98 related articles for article (PubMed ID: 8863809)
1. Chemistry of the pyrrolo[1,2-alpha]benzimidazole antitumor agents: influence of the 7-substituent on the ability to alkylate DNA and inhibit topoisomerase II.
Zhou R; Skibo EB
J Med Chem; 1996 Oct; 39(21):4321-31. PubMed ID: 8863809
[TBL] [Abstract][Full Text] [Related]
2. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems.
Boruah RC; Skibo EB
J Med Chem; 1994 May; 37(11):1625-31. PubMed ID: 8201596
[TBL] [Abstract][Full Text] [Related]
4. Chemistry and DNA alkylation reactions of aziridinyl quinones: development of an efficient alkylating agent of the phosphate backbone.
Skibo EB; Xing C
Biochemistry; 1998 Oct; 37(43):15199-213. PubMed ID: 9790684
[TBL] [Abstract][Full Text] [Related]
5. Pyrrolo[1,2-a]benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity.
Schulz WG; Islam I; Skibo EB
J Med Chem; 1995 Jan; 38(1):109-18. PubMed ID: 7837221
[TBL] [Abstract][Full Text] [Related]
6. Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents.
Craigo WA; LeSueur BW; Skibo EB
J Med Chem; 1999 Aug; 42(17):3324-33. PubMed ID: 10464019
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolobenzimidazoles linked to heterocycles and peptides. Design of DNA base pair specific phosphate hydrolyzing agents and novel cytotoxic agents.
Ghodousi A; Huang X; Cheng Z; Skibo EB
J Med Chem; 2004 Jan; 47(1):90-100. PubMed ID: 14695823
[TBL] [Abstract][Full Text] [Related]
8. First synthesis of an aziridinyl fused pyrrolo[1,2-a]benzimidazole and toxicity evaluation towards normal and breast cancer cell lines.
Bonham S; O'Donovan L; Carty MP; Aldabbagh F
Org Biomol Chem; 2011 Oct; 9(19):6700-6. PubMed ID: 21808774
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolo[1,2-a]benzimidazole-based aziridinyl quinones. A new class of DNA cleaving agent exhibiting G and A base specificity.
Skibo EB; Schulz WG
J Med Chem; 1993 Oct; 36(21):3050-5. PubMed ID: 8230090
[TBL] [Abstract][Full Text] [Related]
10. Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones.
Xing C; Skibo EB
Biochemistry; 2000 Sep; 39(35):10770-80. PubMed ID: 10978162
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
Islam I; Skibo EB; Dorr RT; Alberts DS
J Med Chem; 1991 Oct; 34(10):2954-61. PubMed ID: 1920349
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of benzimidazole-based DNA-cleaving agents. Comparison of benzimidazole, pyrrolobenzimidazole, and tetrahydropyridobenzimidazole analogues.
Skibo EB; Islam I; Heileman MJ; Schulz WG
J Med Chem; 1994 Jan; 37(1):78-92. PubMed ID: 8289204
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of topoisomerase II based on the benzodiimidazole and dipyrroloimidazobenzimidazole ring systems: controlling DT-diaphorase reductive inactivation with steric bulk.
Schulz WG; Skibo EB
J Med Chem; 2000 Feb; 43(4):629-38. PubMed ID: 10691689
[TBL] [Abstract][Full Text] [Related]
16. The influence of the aziridinyl substituent of benzimidazoles and benzimidazolequinones on toxicity towards normal and Fanconi anaemia cells.
Fahey K; O'Donovan L; Carr M; Carty MP; Aldabbagh F
Eur J Med Chem; 2010 May; 45(5):1873-9. PubMed ID: 20122765
[TBL] [Abstract][Full Text] [Related]
17. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
18. Terbenzimidazoles: influence of 2"-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons.
Kim JS; Yu C; Liu A; Liu LF; LaVoie EJ
J Med Chem; 1997 Aug; 40(18):2818-24. PubMed ID: 9288163
[TBL] [Abstract][Full Text] [Related]
19. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
20. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
